Immunocore Holdings (IMCR) Change in Accured Expenses (2023 - 2026)

Immunocore Holdings (IMCR) has reported Change in Accured Expenses for 4 consecutive years, with -$8.3 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Accured Expenses rose 24.13% year-over-year to -$8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.5 million (down 55.23% YoY) and the FY2025 annual result came in at $15.9 million, down 77.78% from the prior year.
• Change in Accured Expenses climbed to -$8.3 million in Q1 2026 per IMCR's latest filing, from -$22.0 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for IMCR reached as high as $33.7 million in Q2 2025 and fell as low as -$22.0 million in Q4 2025.
• A 4-year average of $9.1 million and a median of $11.2 million in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses jumped 318.81% — and 2025, when it slumped 1696.98%.
• Year by year, Change in Accured Expenses stood at $16.0 million in 2023, then plunged by 107.67% to -$1.2 million in 2024, then sank by 1696.98% to -$22.0 million in 2025, then surged by 62.31% to -$8.3 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$8.3 million, -$22.0 million, and $15.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.